Llwytho...
Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
The rise in resistant Gram-negative pathogens continues to challenge clinicians treating infections. These resistant infections have inspired the development of new antimicrobial agents, including ceftolozane–tazobactam, a novel β-lactam/β-lactamase inhibitor combination approved by the US Food and...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Clin Risk Manag |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4878668/ https://ncbi.nlm.nih.gov/pubmed/27279744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S83844 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|